Evotec - Research never stops
  • Loading...

Annual Document

In accordance with § 10 of the German Securities Prospectus Act (Wertpapierprospektgesetz, WpPG) listed companies are obliged to provide the general public annually with a document containing or referring to all information published or otherwise made available in the previous twelve months by the company to the general public as per capital market requirements ("Annual Document").

Publications According to § 10 WpPG of Fiscal Year 2009

Date of publication Topic

Financial Reports                  
27 Mar 2009 Annual Report 2008 of Evotec AG Including Consolidated Financial Statements According to IFRS (PDF, 976,74 kB)
27 Mar 2009 Financial_Statements_2008_and_Managem... (3,02 MB)
12 May 2009 First Quarter Report 2009 (PDF, 133,37 kB)
07 Aug 2009 Half Year Report 2009 (PDF, 150,17 kB)
12 Nov 2009 Third Quarter Report 2009 (PDF, 173,67 kB)
Date of publication

Topic

Preliminary Announcement/Financial Calendar
12 Mar 2009

Preliminary Announcement on the Disclosure of Financial Reports in Fiscal Year 2009 According to §§ 37v, 37w, 37y WpHG (Securities Trading Act) (29,04 kB)
03 Nov 2009 Update of the Preliminary Announcement on the Disclosure of Financial Reports in Fiscal Year 2009 ... (28,71 kB)
12 Nov 2009

Financial Calendar for FY 2010 in Q3 Report (Page 24) (173,67 kB)
Date of publication Topic

Adhoc Releases According to § 15 WpHG
06 Mar 2009 Evotec Appoints Dr. Werner Lanthaler as Chief Executive Officer
09 Mar 2009 Evotec and Roche to Develop EVT 101 for Treatment-Resistant Depression
27 Mar 2009 Evotec Restructures and Implements "Evotec 2012 - Action Plan to Focus and Grow"
14 Apr 2009 Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302
05 May 2009 Evotec to Re-engineer Drug Discovery and Development Operations
07 May 2009 Evotec Acquires Zebrafish Screening Operations of Summit Corporation
29 Jun 2009 Evotec Announces the Successful Completion of the First Phase I Study with EVT 401
06 Aug 2009 Evotec Accelerates Growth Strategy of its Discovery Alliance Business with Acquisition of Indian RSIPL
08 Sep 2009 Evotec starts Phase I with EVT 103, an NR2B-selective NMDA receptor antagonist
09 Nov 2009 Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration
Date of transaction Transaction type, number, name & function Place, price & transaction volume

Directors Dealings According to § 15a WpHG
06 Mar 2009 Purchase of 3,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.6900, EUR 2,070.00
06 Mar 2009 Purchase of 25,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.7169736, EUR 17,924.34
27 Mar 2009 Purchase of 40,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.831375, EUR 33,255.00
16 Apr 2009 Purchase of 31,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.6474193, EUR 20,070.00
22 Apr 2009 Purchase of 15,900 Shares by Werner Lanthaler, CEO XETRA, EUR 0.66, EUR 10,494.00
12 May 2009 Purchase of 37,671 Shares by Werner Lanthaler, CEO XETRA, EUR 0.65, EUR 24,486.15
13 May 2009 Purchase of 12,329 Shares by Werner Lanthaler, CEO XETRA, EUR 0.65, EUR 8,0138.85
14 May 2009 Purchase of 31,250 Shares by Werner Lanthaler, CEO XETRA, EUR 0.6370585, EUR 19,908.08
15 May 2009 Purchase of 65,351 Shares by Werner Lanthaler, CEO XETRA, EUR 0.65, EUR 42,478.15
18 May 2009 Purchase of 11,649 Shares by Werner Lanthaler, CEO XETRA, EUR 0.65, EUR 7,571.85
03 Jun 2009 Purchase of 13,350 Shares by Werner Lanthaler, CEO XETRA, EUR 0.7496629, EUR 10,007.999715
17 Jun 2009 Purchase of 4,900 Shares by Werner Lanthaler, CEO XETRA, EUR 0.7600, EUR 3,724.00
18 Jun 2009 Purchase of 3,720 Shares by Werner Lanthaler, CEO XETRA, EUR 0.7600, EUR 2,827.20
19 Jun 2009 Purchase of 15,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.7900, EUR 11,850.00
29 Jun 2009 Purchase of 11,000 Shares by Werner Lanthaler, CEO XETRA, EUR 0.9300, EUR 10,230.00
11 Aug 2009 Purchase of 25,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.4400, EUR 36,000.00
27 Aug 2009 Purchase of 4,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.60, EUR 6,400.00
01 Sep 2009 Purchase of 30,000 Shares by Mario Polywka, COO XETRA, GBP 1.345, GBP 40,350.00
02 Sep 2009 Purchase of 10,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.4900, EUR 14,900.00
21 Sep 2009 Purchase of 10,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.4500, EUR 14,500.00
22 Sep 2009 Purchase of 10,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.4400, EUR 14,400.00
26 Nov 2009 Purchase of 10,000 Shares by Werner Lanthaler, CEO XETRA, EUR 1.9927, EUR 19,927.00
Date of publication

Topic

Shareholdings According to § 26, Paragraph 1 WpHG
13 Jul 2009

Stichting Pensioenfonds ABP, THe Netherlands
01 Oct 2009

Roland Oetker, Germany /ROI Verwaltungsgesellschaft mbH, Germany
Date of publication

Topic

Publications as per Exchange Rules According to §30b WpHG

>Annual General Meeting
27 Apr 2009 Convening of the AGM_electronic Federal Gazette (in German only) (133,66 kB)
27 Apr 2009

Invitation of the AGM2009_Agenda.pdf

27 Apr 2009 Convening of the AGM_FAZ (in German only) (125,35 kB)
Date of publication

Topic

Others
10 Jun 2009 Resolution on the Authorisation to Acquire and Use Trasury Stock_electronic Federal Gazette (in German only) (32,86 kB)
10 / 11 Jun 2009 Resolution on the Authorisation to Acquire and Use Treasury Stock_Börsen-Zeitung (in German only) (29,56 kB)
30 Jul 2009 Resolution on Creating Conditional Capital_electronic Federal Gazette (in German only) (49,27 kB)
30 Jul 2009 Resolution on Creating Conditional Capital_FAZ (in German only) (27,23 kB)
16 Jan 2009 Receipt of Abandonment of Action_electronic Federal Gazette (in German only) (28,76 kB)
Date of publication

Topic

Publications as per Exchange Rules According to §30e WpHG
9 Jun 2009 Other Capital Market Information (29,22 kB)
Foreign Publications
2008 Form 20-F (435,04 kB)
Other SEC-Filings

In case an internet link is broken, you can obtain the information given or linked on this page for free by contacting us at investor.relations@evotec.com.